Findings published in the Journal of Diabetes and its Complications found that 77.3% of 4,398 adults with type 2 diabetes had a serum magnesium level of at least 0.74 mmol/L after taking 10 mg of dapagliflozin daily for 24 weeks, compared with 29.5% of those in the placebo group. The analysis also showed that SGLT2 inhibitor treatment more effectively reduced blood pressure and heart rate measures than placebo.
Study shows improved magnesium levels among SGLT2 inhibitor users
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.